Ocuphire Pharma, Inc. (OCUP)

USD 1.17

(-12.03%)

Market Cap (In USD)

31.73 Million

Revenue (In USD)

19.04 Million

Net Income (In USD)

-9.98 Million

Avg. Volume

149.15 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.0715-3.3994
PE
-
EPS
-
Beta Value
0.309
ISIN
US67577R1023
CUSIP
67577R102
CIK
1228627
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. George Magrath M.B.A., M.D., M.S.
Employee Count
-
Website
https://www.ocuphire.com
Ipo Date
2005-11-10
Details
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances; and Phase 2b clinical trial for pharmacologically induced mydriasis, as well as that has completed Phase 2 VEGA-1 trial for presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. Ocuphire Pharma, Inc. is headquartered in Farmington Hills, Michigan.